Ibio, INC. (IBIO) — 8-K Filings

8-K Filings (31)

• 8-K Filing — Apr 8, 2026
• iBio, Inc. Submits Matters to Security Holders — Nov 21, 2025 Risk: medium
  On November 20, 2025, iBio, Inc. filed an 8-K report to announce that it submitted matters to a vote of its security holders. The filing does not specify the na
• iBio, Inc. Files 8-K Report — Nov 4, 2025 Risk: low
  On November 4, 2025, iBio, Inc. filed an 8-K report. The filing indicates that the company is located at 11750 Sorrento Valley Road, Suite 200, San Diego, Calif
• iBio, Inc. Files 8-K Report — Oct 30, 2025 Risk: low
  On October 30, 2025, iBio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation F
• iBio, Inc. Files 8-K: Material Agreement & Disclosures — Aug 21, 2025 Risk: medium
  On August 19, 2025, iBio, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also made
• iBio, Inc. Files 8-K with Financial Updates — Aug 18, 2025 Risk: medium
  On August 18, 2025, iBio, Inc. filed an 8-K report detailing significant events. The filing includes information on the company's results of operations and fina
• iBio Faces NYSE American Delisting Threat — Aug 1, 2025 Risk: high
  On July 29, 2025, iBio, Inc. filed an 8-K report indicating a potential delisting from the NYSE American. The company received a notice from the exchange regard
• iBio, Inc. Files 8-K with Regulatory Disclosures — Jun 24, 2025 Risk: medium
  On June 24, 2025, iBio, Inc. filed an 8-K report detailing several events. The company announced a Regulation FD Disclosure, indicating a public disclosure of m
• iBio, Inc. Files 8-K Report — Jun 18, 2025 Risk: low
  On June 17, 2025, iBio, Inc. filed an 8-K report detailing other events and financial statements. The company, formerly known as iBioPharma, Inc., is incorporat
• iBio, Inc. Files 8-K: Material Agreement, Exhibits — Apr 22, 2025 Risk: medium
  On April 21, 2025, iBio, Inc. entered into a Material Definitive Agreement. The filing also includes a Regulation FD Disclosure and Financial Statements and Exh
• iBio, Inc. Files 8-K Report — Apr 8, 2025 Risk: low
  On April 8, 2025, iBio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD d
• iBio, Inc. Files 8-K Report — Apr 7, 2025 Risk: low
  On April 7, 2025, iBio, Inc. filed an 8-K report detailing a Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The filing does not
• iBio Faces NYSE American Delisting Risk — Feb 19, 2025 Risk: high
  On February 19, 2025, iBio, Inc. filed an 8-K to report its notice of delisting or failure to satisfy continued listing rules. The company is facing potential d
• iBio, Inc. Files 8-K: Material Agreement, Equity Sales — Jan 13, 2025 Risk: medium
  On January 10, 2025, iBio, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company also repo
• iBio, Inc. Files 8-K Report — Jan 10, 2025 Risk: low
  On January 10, 2025, iBio, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, along with financial statements a
• iBio, Inc. Files 8-K with Material Agreements and Equity Sales — Jan 2, 2025 Risk: medium
  On December 31, 2024, iBio, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company also reported on u
• iBio, Inc. Announces Stockholder Meeting for Reverse Stock Split — Nov 25, 2024 Risk: medium
  On November 21, 2024, iBio, Inc. filed an 8-K report detailing its financial results and announcing a special meeting of stockholders. The meeting, scheduled fo
• iBio, Inc. Files 8-K: Financials and Operations Update — Nov 12, 2024 Risk: medium
  On November 12, 2024, iBio, Inc. filed an 8-K report detailing its financial results and condition. The company, formerly known as iBioPharma, Inc. and InB:Biot
• 8-K Filing — Oct 23, 2024
• iBio Appoints Thomas D'Alonzo CEO, Hikes Executive Compensation — Jul 26, 2024 Risk: medium
  On July 23, 2024, iBio, Inc. announced the appointment of Thomas L. D'Alonzo as its new Chief Executive Officer and a member of the Board of Directors. D'Alonzo
• iBio Appoints Thomas D'Alonzo CEO, Sets Salary — Jul 9, 2024 Risk: medium
  On July 2, 2024, iBio, Inc. announced the appointment of Thomas L. D'Alonzo as Chief Executive Officer and a member of the Board of Directors. D'Alonzo, previou
• iBio, Inc. Files 8-K: Material Definitive Agreement — Jul 3, 2024 Risk: medium
  On July 3, 2024, iBio, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and exhibits, but speci
• iBio, Inc. Reports Key Corporate Events and Asset Changes — Jun 5, 2024 Risk: medium
  On May 31, 2024, iBio, Inc. reported the termination of a material definitive agreement and the completion of an acquisition or disposition of assets. The compa
• 8-K Filing — Jun 3, 2024
• iBio, Inc. Secures $1.5M in Equity Financing — May 20, 2024 Risk: medium
  On May 14, 2024, iBio, Inc. entered into a Material Definitive Agreement, specifically a Securities Purchase Agreement, with an accredited investor. This agreem
• iBio, Inc. Files 8-K for Operations and Financials — May 13, 2024 Risk: low
  On May 13, 2024, iBio, Inc. filed an 8-K report to disclose information regarding its results of operations and financial condition, as well as financial statem
• iBio Secures Up to $10M in Equity Financing — Apr 1, 2024 Risk: medium
  On March 26, 2024, iBio, Inc. entered into a Material Definitive Agreement, specifically a Securities Purchase Agreement, with an accredited investor. This agre
• iBio Reports Material Agreement & Asset Transaction — Feb 26, 2024 Risk: medium
  iBio, Inc. filed an 8-K on February 26, 2024, reporting an event that occurred on February 25, 2024. The filing indicates an entry into a material definitive ag
• iBio, Inc. Changes Certifying Accountant — Feb 21, 2024 Risk: low
  iBio, Inc. filed an 8-K on February 21, 2024, reporting a change in its certifying accountant. The earliest event reported was February 15, 2024. The filing ind
• iBio Reports New Material Agreement & Financial Obligation — Jan 19, 2024
  iBio, Inc. filed an 8-K on January 19, 2024, reporting an event that occurred on January 16, 2024, related to entering a material definitive agreement and creat
• iBio Changes Headquarters to Bryan, Texas — Jan 8, 2024
  iBio, Inc. filed an 8-K on January 8, 2024, primarily to update its corporate address from 600 Madison Avenue, Suite 1601, New York, NY to 8800 HSC Parkway, Bry

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX